Literature DB >> 9269227

Cholera.

J L Sánchez1, D N Taylor.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9269227     DOI： 10.1016/S0140-6736(97)04486-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Solar disinfection of drinking water protects against cholera in children under 6 years of age.

Authors:  R M Conroy; M E Meegan; T Joyce; K McGuigan; J Barnes
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Diarrhea in the International Traveler.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

4.  Climate variability and the outbreaks of cholera in Zanzibar, East Africa: a time series analysis.

Authors:  Rita Reyburn; Deok Ryun Kim; Michael Emch; Ahmed Khatib; Lorenz von Seidlein; Mohammad Ali
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

5.  New developments in the understanding of cholera.

Authors:  T Butler
Journal:  Curr Gastroenterol Rep       Date:  2001-08

6.  Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.

Authors:  M B Cohen; R A Giannella; G A Losonsky; D R Lang; S Parker; J A Hawkins; C Gunther; G A Schiff
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

7.  Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.

Authors:  C O Tacket; M B Cohen; S S Wasserman; G Losonsky; S Livio; K Kotloff; R Edelman; J B Kaper; S J Cryz; R A Giannella; G Schiff; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

Authors:  Mitchell B Cohen; Ralph A Giannella; Judy Bean; David N Taylor; Susan Parker; Amy Hoeper; Stephen Wowk; Jennifer Hawkins; Sims K Kochi; Gilbert Schiff; Kevin P Killeen
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 9.  Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected).

Authors:  Patricia M Graves; Jonathan J Deeks; Vittorio Demicheli; Tom Jefferson
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

10.  Field evaluation of a rapid immunochromatographic dipstick test for the diagnosis of cholera in a high-risk population.

Authors:  Xuan-Yi Wang; M Ansaruzzaman; Raul Vaz; Catarina Mondlane; Marcelino E S Lucas; Lorenz von Seidlein; Jacqueline L Deen; Sonia Ampuero; Mahesh Puri; Taesung Park; G B Nair; John D Clemens; Claire-Lise Chaignat; Minoarisoa Rajerison; Farida Nato; Jean-Michel Fournier
Journal:  BMC Infect Dis       Date:  2006-02-01       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.